Genetic Technologies Share Price and Company Fundamentals

0.000 (0.000%)
52 week
0.003 - 0.009

Last traded: Yesterday at 5:56 AM

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield




Market cap


Enterprise value


Company profile

Primary activitiesLicensing of biotechnology patents covering the non-coding regions of the genome and other genetic research and testing.
Industry / SectorDiagnostics & Research / Healthcare
Full time employees18
Mailing address60-66 Hanover Street Fitzroy VIC 3065 Australia
Phone / Fax61 3 8412 7000 / 61 3 8412 7040


More: Genetic Technologies Dividend history, yield and payout ratio

Dividend yield


Dividend amount


Payout ratio


Genetic Technologies paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.GTG dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.

GTG's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Aug 2022, following are the company executives and directors listed on Genetic Technologies.

NameTitleAgeTotal Pay
Mr. Simon MorrissChief Exec. Officer376.04k
Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICDCFO & Company Sec.54288.58k
Mr. Stanley SackChief Operating Officer56143.28k
Dr. Richard Allman Ph.D.Chief Scientific Officer61203.21k
Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIAConsultant
Mr. Carl S. Stubbings BScChief Commercial Officer

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Genetic Technologies is and its enterprise value is .

The GTG's stocks Beta value is 1.30 making it 30% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Genetic Technologies (GTG)

Genetic Technologies (ASX:GTG) Frequently Asked Questions

1. What is Genetic Technologies's Stock Symbol?

Genetic Technologies trades on ASX under the ticker symbol "GTG".

2. What is Genetic Technologies's stock price today?

One share of GTG stock can currently be purchased for approximately $0.004.

3. How can I contact Genetic Technologies?

Genetic Technologies's mailing address is 60-66 Hanover Street Fitzroy VIC 3065 Australia. The company can be reached via phone at 61 3 8412 7000.

4. What is Genetic Technologies's official website?

The official website of Genetic Technologies is

5. Which share registry manages Genetic Technologies's stock?

Genetic Technologies's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.